Market capitalization | $33.61m |
Enterprise Value | $-36.03m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.80 |
P/B ratio (TTM) P/B ratio | 0.44 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-60.54m |
Free Cash Flow (TTM) Free Cash Flow | $-45.03m |
Cash position | $75.31m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a NextCure, Inc. forecast:
3 Analysts have issued a NextCure, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.17 -3.17 |
30%
30%
|
|
EBITDA | -57 -57 |
12%
12%
|
EBIT (Operating Income) EBIT | -61 -61 |
13%
13%
|
Net Profit | -59 -59 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
Head office | United States |
CEO | Michael Richman |
Employees | 82 |
Founded | 2015 |
Website | www.nextcure.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.